Business Context and Reporting Period
Company: ORAMED PHARMACEUTICALS INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 7, 2013
Event: Approval of listing application for common stock on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the approval of the registrant's application to list its shares of common stock on The Nasdaq Capital Market. Trading is scheduled to commence on February 11, 2013, under the symbol ORMP.
Guidance, Outlook, and Risks
The filing references a Press Release (Exhibit 99.1) but does not include specific management commentary, financial guidance, risk factors, or contingencies within the body of this 8-K text.
Investor Verification Checklist
- Verify the commencement of trading on February 11, 2013, under the symbol ORMP.
- Review the attached Press Release (Exhibit 99.1) for additional context on the listing approval.
- Confirm the company's compliance with Nasdaq Capital Market listing requirements.